The U.S. Food and Drug Administration has approved Gleevec (imatinib mesylate) for a new indication: keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor, or GIST.
A convergence of research has created a great deal of speculation on the far-reaching implications of Gleevec (imatinib mesilate) for patients suffering with the autoimmune disease scleroderma.
